industry-specific-commercialisation-playbook
Tailor the commercialisation strategy and expectations by industry: life sciences, deep tech, software, societal/humanities-based innovations.
SKILL.mdspecialisation-packs/research-commercialisation/skills/industry-specific-commercialisation-playbook/SKILL.md
GitHubIndustry-Specific Commercialisation Playbook
Purpose
Tailor the commercialisation strategy and expectations by industry: life sciences, deep tech, software, societal/humanities-based innovations.
Based on
the owner's published commercialisation guide (owner, 2025). Chapter "Different Paths by Industry" (pp. 29-34) — case examples Vaccitech/BioNTech, IQM Finland/ArtiQ, DeepMind, the UK's Aspect programme.
- Life sciences: a long (10+ years), expensive, regulated pathway; often partnership/acquisition by a larger player later
- Deep tech: prototype and pilot production stages, specialised equipment, strong IP protection as an advantage
- Software: the fastest cycle, low capital need, often nothing patentable
- Social sciences/humanities: IP-light, "lean spin-out" approach (the UK's Aspect programme)
Method
- Life sciences (pharma/biotech): expect a 10+ year pathway and significant capital; focus on early-stage evidence (preclinical/Phase 1) and partnership/acquisition later. University equity can justifiably be higher (up to c. 25%).
- Deep tech / engineering: expect prototype and pilot production stages, specialised equipment and facilities. Strong patent protection is a competitive advantage. Seek deep industry expertise for advisors — a software-background mentor is not enough.
- Software and digital innovations: the fastest development cycle, low initial capital, often nothing patentable (know-how/copyright/first-mover advantage). University equity is typically lower (≤10%). Speed and continuous iteration are decisive, not the original IP.
- Social sciences/humanities/"impact" spin-outs: often IP-light, low capital need, fast revenue generation through consulting or a service. "Lean spin-out": minimal initial investment, fast customer interaction, iterative refinement.
- Identify the regulatory environment early in every industry (FDA/EMA, financial regulation, energy certifications, education sector procurement rules) and secure an experienced advisor.
- Summarise your own industry "playbook": pharma = patent–prototype– publish–partner (long, capital-intensive); deep tech = patent–prototype– prove in pilots–seek strategic investors; software = build fast–acquire users–pivot–scale; societal = prove impact–seek blended funding (grants + revenue).
- Study prior spin-outs in your own field — which pathway did they take?
(see
../../references/case-studies.md).
Gotchas
- The four archetypes (life sciences, deep tech, software, social science/humanities) are illustrative buckets from the guide's case examples, not an exhaustive taxonomy — a result that straddles two (e.g. an AI-driven diagnostic device) should default to the higher-friction pathway's regulatory and IP assumptions, not the faster one's.
- The equity benchmarks (≤10% software, up to ~25% life sciences) are
indicative ranges, not your institution's actual terms — use them as a
sanity check on a number the TTO proposes, then confirm the real figure
via
tto-engagement-strategyandip-disclosure-and-ownership-check. - Step 2 explicitly says a software-background mentor is "not enough" for deep tech — satisfying the advisor requirement with whoever's already on the team, rather than someone with the specific industry expertise, misses the point of the step.
- The timelines and cost figures are explicitly indicative (see "does NOT do") — quoting "10+ years" or "fastest cycle" to a funder as a commitment rather than a planning heuristic overstates what the guide's examples actually support.
- Step 7 (study prior spin-outs in your field) only transfers cleanly when the comparison case shares both sub-domain and regulatory regime — a similar-looking spin-out under a different regulator (e.g. FDA vs. EMA) can lead to copying a pathway that doesn't actually apply.
What this skill does NOT do
- Does not perform regulatory classification for you (e.g. EU AI Act classification of an AI system) — use separate regulatory expertise.
- Does not give a precise timeline or cost estimate — the examples are indicative, not guarantees.
Continue from here
- Next in this pack:
../funding-pathway-design/SKILL.md— Build a funding strategy that combines non-dilutive and dilutive funding in the right order, and manage runway. - Pack's shared guardrails:
../../CLAUDE.md - Overview of the full journey:
../commercialisation-journey-roadmap/SKILL.md
References
../../references/case-studies.md— 7 spin-out examples from different industries and regions../../references/terminology.md— the handbook's glossary../../references/sources.md— the handbook's own source references../../CLAUDE.md— the pack's shared guardrails